Pegaspargase (polyethylene glycol-L-asparaginase)

Clinical Immunotherapeutics

Volumn 5, Issue 6, 1996, Pages 492-496

  Patel, Sanjay S ^a   Benfield, Paul ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD TOXICITY; CHILL; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEVER; HUMAN; LIVER TOXICITY; LYMPHOBLASTOMA; NAUSEA; NONHUMAN; PAIN; PHARMACODYNAMICS; PRIORITY JOURNAL; SHORT SURVEY; VOMITING;

EID: 0029884152     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259345     Document Type: Short Survey

References (24)

1. Kafkewitz D, Bendich A, Enzyme-induced asparagine and glutamine depletion and immune system function. Am J Clin Nutr !983Jun;37: 1025-30
2. Kealing MJ, Holmes R, Lerner S, et al, L-asparaginase and PEG asparaginase - past, present, and future. Leuk Lymphoma 1993; lüSuppl.: 153-7
3. Land VJ, Sutow WW, Fernbach DJ, et al, Toxicity öl L-asparaginase in children with advanced leukemia. Cancer 1972 Äug; 30 (2): 339-47
4. Kawashima K, Takeshima H, Higashi Y, et al. High efficacy of monomethoxypolyethyleneglycol-conjugated L-asparaginase (PEGi-ASP) in two patients with hematological malignancies. Leuk Res 1991; 15 (6): 525-30
5. Capizzi RL, Bertino JR, Skeel RT, et al, L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971; 74: 893-901
6. Hill JM, Roberts J, Loeb E, et al, L-asparaginase therapy for leukemia and other malignant neoplasms: remission in human leukemia. JAMA 1967 Nov; 202 (9): 882-8
7. Dolowy WC, Henson D, Cornet J, et al, Toxic and antineoplastic effects of L-asparaginase: study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer 1966 Dec; 19(12): 1813-9
8. Oetlgen HF, Old LJ, Boyse EA, el al, Inhibition of leukemias in man by L-asparaginase. Cancer Res 1967; 27 (Pt 1): 2619-31
9. Crowther D, L-asparaginase and human malignant disease. Nature 1971 Jan; 229: 168-71
10. Clarkson B, Krakoff I, Burchenal J, et al, Clinical results of treatment with E. call L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer 1970 Feb; 25 (2): 279-305
11. Park YK, Abuchowski A, Davis S, et al, Pharmacology ofEscherichiacoli-L-asparaginase polyethylene glycol adduct. Anticancer Res 1981; I: 373-6
12. Levien TL, Baker DE, Reviews of pegaspargase and oral pilocarpine. Hosp Pharm 1995 Jan; 30 (I ): 54-9
13. Capizzi RL, Asparaginase revisited. Leuk Lymphoma 1993; 10 Suppl.: 147-50
14. Product Information, Rhône-Poulenc Rorer. Oncaspar. In: Gole WJ, editor. Physicians' Desk Reference. 49th ed. Montvale, (NJ): Medical Economics Data Production Co., 1995: 1976-8
15. MacEwen EG, Rosenthal R, Malus R, et al, A preliminary study on the evaluation of asparaginase: polyethylene glycol conjugate against canine malignant lymphoma. Cancer 1987 Jun; 59(121:2011-5
16. Ho DH, Wang C-Y, Lin J-R, et al. Polyethylene glycol-L-asparaginase and L-asparaginase studies in rabbits. Drug Metab Dispos 1988 Jan-Feb; 16(1): 27-9
17. Kamisaki Y, Wada H, Yagura T, et al, Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther 1981 ; 216 (2): 410-4
18. Ho DH, Brown NS, Yen A, et al, Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos 1986 May-Jun; 14(31:349-52
19. Asselin BL, Whitin JC, Coppola DJ, et al, Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993Sep; II (9): 1780-6
20. Kurtzberg J, A new look at PEG-L-asparaginase and other asparaginases in hematological malignancies [abstract no. 49|. Cancer Invest 1994; 12 Suppl. 1: 59-60
21. Ettinger LJ, Kurtzberg J, Voûte PA, et al, An open-label, multicenter study of polyethylene glycol-L-asparaginase for the trealmenl of acute lymphoblastic leukemia. Cancer 1995 Mar; 75(5): 1176-81
22. Capizzi RL, Holcenberg JS, Asparaginase. In: Holland JF, Frei E, Bast RC, et al., editors. Cancer medicine. 3rd ed. Philadelphia: Lea and Febiger, 1993: 796-805
23. Ettinger LJ, Lerner ED, A toxicity study of Oncaspar (Pegasparaginase) in children with acute lymphoblastic leukemia (ALL) {abstract no. 354]. Med Pediatr Oncol 1994; 23 (3): 278
24. Greffe B, Lambert-Kerzner A, Eno M, Hypercoagulable/prethrombotic state associated with PEG-L-asparaginase in pé diatrie leukemie patients [abstract no. 197|. Thromb Haemost 1993 Jun; 69: 599